Insulet Corporation (PODD)
| Market Cap | 11.11B -35.8% |
| Revenue (ttm) | 2.90B +31.9% |
| Net Income | 302.80M -24.7% |
| EPS | 4.29 -22.7% |
| Shares Out | 69.26M |
| PE Ratio | 37.39 |
| Forward PE | 24.12 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,827,246 |
| Open | 153.09 |
| Previous Close | 151.28 |
| Day's Range | 152.52 - 163.18 |
| 52-Week Range | 148.31 - 354.88 |
| Beta | 1.20 |
| Analysts | Buy |
| Price Target | 293.81 (+83.17%) |
| Earnings Date | May 6, 2026 |
About PODD
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; Omnipod DASH insulin management system that features a Bluetooth enabled pod that is controll... [Read more]
Financial Performance
In 2025, Insulet's revenue was $2.71 billion, an increase of 30.73% compared to the previous year's $2.07 billion. Earnings were $247.10 million, a decrease of -40.93%.
Financial StatementsAnalyst Summary
According to 21 analysts, the average rating for PODD stock is "Buy." The 12-month stock price target is $293.81, which is an increase of 83.17% from the latest price.
News
Insulet price target lowered to $237 from $277 at Goldman Sachs
Goldman Sachs lowered the firm’s price target on Insulet (PODD) to $237 from $277 and keeps a Buy rating on the shares. The company’s Q1 headline results and guidance updates
Insulet price target lowered to $263 from $355 at Raymond James
Raymond James lowered the firm’s price target on Insulet (PODD) to $263 from $355 and keeps an Outperform rating on the shares. Insulet’s Q1 results were mixed with a slow
Insulet price target lowered to $280 from $325 at RBC Capital
RBC Capital analyst Shagun Singh lowered the firm’s price target on Insulet (PODD) to $280 from $325 and keeps an Outperform rating on the shares. The company delivered another solid
Insulet price target lowered to $200 from $330 at Bernstein
Bernstein lowered the firm’s price target on Insulet (PODD) to $200 from $330 and keeps an Outperform rating on the shares following quarterly results. With shares down 56% since November,
Insulet price target lowered to $249 from $435 at Canaccord
Canaccord analyst William Plovanic lowered the firm’s price target on Insulet (PODD) to $249 from $435 and keeps a Buy rating on the shares. The firm said Insulet reported a
Insulet price target lowered to $248 from $360 at Baird
Baird lowered the firm’s price target on Insulet (PODD) to $248 from $360 and keeps an Outperform rating on the shares. The firm updated its model following Q1 results which
Insulet price target lowered to $250 from $350 at Stifel
Stifel lowered the firm’s price target on Insulet (PODD) to $250 from $350 and keeps a Buy rating on the shares.
Insulet price target lowered to $275 from $340 at JPMorgan
JPMorgan lowered the firm’s price target on Insulet (PODD) to $275 from $340 and keeps an Overweight rating on the shares.
Insulet price target lowered to $210 from $300 at Oppenheimer
Oppenheimer lowered the firm’s price target on Insulet (PODD) to $210 from $300 and keeps an Outperform rating on the shares. The firm notes Insulet reported Q1 sales of $762M,
Insulet price target lowered to $200 from $240 at Evercore ISI
Evercore ISI lowered the firm’s price target on Insulet (PODD) to $200 from $240 and keeps an Outperform rating on the shares.
Insulet price target lowered to $250 from $315 at Truist
Truist analyst Richard Newitter lowered the firm’s price target on Insulet (PODD) to $250 from $315 and keeps a Buy rating on the shares. After a 10% sell-off in the
Insulet price target lowered to $198 from $286 at Barclays
Barclays analyst Matt Miksic lowered the firm’s price target on Insulet (PODD) to $198 from $286 and keeps an Underweight rating on the shares. The firm updated the company’s model
Insulet reports Q1 adjusted EPS $1.42, consensus $1.19
Reports Q1 revenue $761.7M, consensus $730.1M. “We started the year strong, delivering continued growth momentum and robust operating margin expansion in the first quarter,” said Ashley McEvoy, Presid...
Insulet sees Q2 total revenue growth 20%-22%
Sees Q2 Omnipod revenue growth 21%-23%.
Insulet backs FY26 adjusted EPS growth view at least 25%
Raises FY26 revenue growth view to 21%-23% from 20%-22%.
Insulet price target lowered to $260 from $320 at BTIG
BTIG lowered the firm’s price target on Insulet (PODD) to $260 from $320 and keeps a Buy rating on the shares after the company reported Q1 earnings, increased its 2026
Insulet price target lowered to $175 from $230 at Citi
Citi analyst Joanne Wuensch lowered the firm’s price target on Insulet (PODD) to $175 from $230 and keeps a Neutral rating on the shares. Q1 featured “a very nice beat
Insulet Earnings Call Transcript: Q1 2026
Q1 2026 delivered 30% constant currency revenue growth, margin expansion, and strong new customer starts, prompting a raised full-year revenue outlook to 21%-23%. Robust U.S. and international performance, innovation launches, and disciplined execution support confidence in sustained growth and profitability.
Insulet lifts annual revenue forecast after quarterly beat on strong insulin pump demand
Insulet raised its annual revenue growth forecast on Wednesday after reporting better-than-expected quarterly results, driven by strong demand for its tubeless insulin pumps that eliminate the need ...
Insulet Reports First Quarter 2026 Results
ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced i...
Insulet Unveils 2025 Sustainability Report Highlighting Strong Momentum Across Key Priorities
ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced t...
Insulet Initiates EVOLVE Pivotal Study to Advance Fully Closed-Loop Automated Insulin Delivery System for Type 2 Diabetes
ACTON, Mass.--(BUSINESS WIRE)--Insulet Initiates EVOLVE Pivotal Study to Advance Fully Closed-Loop Automated Insulin Delivery System for Type 2 Diabetes.
Insulet to Participate in BofA Securities 2026 Health Care Conference
ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced that management will prese...
Insulet to Announce First Quarter 2026 Financial Results on May 6, 2026
ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced i...
Insulet Appoints Mike Panos as Chief Commercial Officer
ACTON, Mass.--(BUSINESS WIRE)--Insulet Appoints Mike Panos as Chief Commercial Officer.